Corcept Therapeutics is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53 ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for ...

Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at ...

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.